SOURCE: Vycor Medical Inc

Vycor Medical Inc

December 16, 2010 09:00 ET

Vycor Medical's Newly-Acquired Therapeutic and Diagnostic Vision Restoration Subsidiary (NovaVision) on Track to Provide Patient Services in January

BOHEMIA, NY--(Marketwire - December 16, 2010) - Vycor Medical, Inc. (OTCBB: VYCO) (, a medical device company that designs, develops and markets next generation neurosurgery retraction devices, announced that its newly-acquired subsidiary, NovaVision, Inc. (together with its German subsidiary NovaVision AG, "NovaVision"), is on track to take on patients for its non-invasive Vision Restoration Therapy ("VRT").

NovaVision makes and provides FDA-cleared and CE-marked medical devices to provide VRT, which is a patient-specific, diagnostic and therapeutic platform that has been shown in clinical testing to aid in the restoration of lost vision resulting from neurological conditions such as strokes or traumatic brain injury ("TBI"). Approximately 3,000 patients have received VRT to date.

Vycor announced that it has secured commitments from a number of key personnel from NovaVision's predecessor, including the senior management and technical team in Germany, the chief software developer in the US (David Furshpan) and an additional 6 former employees of NovaVision's predecessor covering disciplines ranging from client services (who interact with clients) to clinical services (who tailor the actual therapy). Previously, Vycor had hired and retained the former VP of Sales and Marketing of the predecessor company (Tom Bridges) who will be an integral component of the team going forward.

Vycor's President, David Cantor, stated that "...we are working to have NovaVision in a position where it will be able to service patients once more in January 2011. NovaVision is currently in the process of reaching out to the physician base who had previously prescribed VRT to ensure its ability to service and attract patients." Mr. Cantor further observed that "...we are confident we will see a strong demand for VRT in the marketplace as we see an ultimate market potential of approximately $10 billion worldwide."

The Company's key strategy is to capitalize on the significant time and money invested to date by leveraging all of the existing academic and clinical studies, which include the six Company-sponsored studies and 14 independent studies, together with patient testimonials. The Company believes that all of this underlying work that has already been undertaken will support the efficacy of the VRT treatment going forward.

Additionally, the Company is presently in discussions with respected physicians in the field who it hopes will join the Company in the common goal of providing Vision Restoration Therapy to the many afflicted stroke and TBI sufferers who have previously not been able to access VRT either because it was not broadly available or too costly. It is the Company's goal to have a web-based solution which will further help address the cost and availability of VRT within the next six months.

About Vycor Medical, Inc.

With corporate offices in Bohemia, NY, Vycor Medical, Inc. (OTCBB: VYCO) is a medical device company committed to making neurological brain, spinal and other surgical procedures safer and more effective and to provide Vision Restoration Therapy to a broad range of prospective clients.

The Company's flagship, Patent Pending ViewSite™ Surgical Access Systems, represent an exciting new breed of retraction technology that holds the potential for speedier, safer and more economical brain, spinal and other surgeries and a quicker patient discharge. Vycor's innovative medical instruments are designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery, and add tangible value to the professional medical community.

The Company also provides Vision Restoration Therapy through its NovaVision, Inc. subsidiary to clients who have had vision impairment as a result of neurological conditions such as strokes and TBI.

For the latest information on the company, including media and other coverage, and to learn more, please see

Safe Harbor Statement

Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast," "anticipate," "estimate," "project," "intend," "expect," "should," "believe," and similar expressions are intended to identify forward-looking statements. These forward looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the abovementioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.

Contact Information